QARYFORV Trademark

Trademark Overview

On Wednesday, June 21, 2023, a trademark application was filed for QARYFORV with the United States Patent and Trademark Office. The USPTO has given the QARYFORV trademark a serial number of 79379321. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, March 29, 2024. This trademark is owned by Boehringer Ingelheim International GmbH. The QARYFORV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention ...
qaryforv

General Information

Serial Number79379321
Word MarkQARYFORV
Filing DateWednesday, June 21, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, March 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of diseases and disorders of the alimentary tract and metabolism; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the blood and blood forming organs; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the cardiovascular system, musculoskeletal system, central nervous system, peripheral nervous system, genitourinary system and respiratory system; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders, damaged skin and tissues; pharmaceutical preparations for the prevention and treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment and prevention of hormonal diseases and disorders; pharmaceutical preparations for the treatment and prevention of infectious diseases and disorders and viral infections; pharmaceutical preparations for the prevention and treatment of oncological and auto-immune diseases and disorders; pharmaceutical preparations, namely, cell based immune therapeutics for treatment of cancer, for treatment of immunological diseases, and treatment of infectious diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 4, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBoehringer Ingelheim International GmbH
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDE

Trademark Events

Event DateEvent Description
Friday, March 29, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, March 29, 2024REFUSAL PROCESSED BY MPU
Tuesday, March 12, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, March 11, 2024NON-FINAL ACTION WRITTEN
Saturday, March 9, 2024ASSIGNED TO EXAMINER
Tuesday, October 10, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, October 4, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 26, 2023LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, September 21, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

qaryforv treatment pharmaceutical prevention preparations disorders diseases system nervous blood skin